Kunyu Yang
Impact in
- Otorhinolaryngology top 0.1%
- Head and Neck Cancer Studies
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Cancer Cells and Metastasis
Papers in
-
- Head and Neck Cancer Studies 37
- Oncology 45
- Cancer Immunotherapy and Biomarkers 27
- Co-authors
- Gang Wu (16 shared papers)Chao Wan (29 shared papers)Gang Wu (25 shared papers)Honglin Jin (18 shared papers)Sheng Zhang (7 shared papers)Tao� Zhang (10 shared papers)Jonathan F. Lovell (14 shared papers)Yajie Sun (26 shared papers)
- Journals
- Theranostics (9 papers)International Journal of Radiation Oncology*Biology*Physics (7 papers)Annals of Oncology (6 papers)Journal for ImmunoTherapy of Cancer (4 papers)Journal of Clinical Oncology (4 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Kunyu Yang
162 papers receiving 7.8k citations
Kunyu Yang's Hit Papers
Peers
Comparison fields: 5 of 121
- Otorhinolaryngology 2.1k
- Oncology 2.1k
- Radiation 372
- Cancer Research 527
- Pulmonary and Respiratory Medicine 1.1k
Countries citing papers authored by Kunyu Yang
This map shows the geographic impact of Kunyu Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunyu Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunyu Yang more than expected).
Fields of papers citing papers by Kunyu Yang
This network shows the impact of papers produced by Kunyu Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunyu Yang. The network helps show where Kunyu Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Kunyu Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 172 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma Hit paper breakdown → | 2019 | 694 |
| 2 | A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma Hit paper breakdown → | 2012 | 510 |
| 3 | Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Hit paper breakdown → | 2020 | 440 |
| 4 | 2012 | 313 | |
| 5 | Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial Hit paper breakdown → | 2021 | 306 |
| 6 | Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 302 |
| 7 | The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma Hit paper breakdown → | 2021 | 276 |
| 8 | 2009 | 237 | |
| 9 | 2020 | 223 | |
| 10 | 2020 | 212 | |
| 11 | 2019 | 168 | |
| 12 | Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 159 |
| 13 | Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309) Hit paper breakdown → | 2023 | 157 |
| 14 | Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma Hit paper breakdown → | 2023 | 156 |
| 15 | 2021 | 133 | |
| 16 | 2011 | 131 | |
| 17 | Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial Hit paper breakdown → | 2022 | 109 |
| 18 | Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial Hit paper breakdown → | 2022 | 108 |
| 19 | 2021 | 101 | |
| 20 | BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study Hit paper breakdown → | 2024 | 99 |
About Kunyu Yang
Kunyu Yang is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Immunology and Radiation, having authored 172 papers that have together received 8k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (37 papers), Cancer Immunotherapy and Biomarkers (27 papers), Radiation Therapy and Dosimetry (12 papers), Advanced Radiotherapy Techniques (12 papers), Immunotherapy and Immune Responses (11 papers), Immune cells in cancer (9 papers), Nanoplatforms for cancer theranostics (9 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Otorhinolaryngology (2.1k citations), Oncology (2.1k citations), Radiation (372 citations), Cancer Research (527 citations) and Pulmonary and Respiratory Medicine (1.1k citations). Kunyu Yang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Gang Wu, Chao Wan, Gang Wu, Honglin Jin, Sheng Zhang, Tao� Zhang, Jonathan F. Lovell, Yajie Sun, Gang Peng and Jun Young Han. Their work appears in journals such as Theranostics, International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology, Journal for ImmunoTherapy of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.